Francesca Giovannenze

@policlinicogemelli.it

Medical and Surgical Sciences, Infectious Diseases Unit
Fondazione Policlinico Universitario A. Gemelli IRCCS

Francesca Giovannenze


            Download Compact PDF  
https://researchid.co/francesca.giovannenze

RESEARCH INTERESTS

Infectious Diseases; MDR organisms; Bacterial infections; viral infections
37

Scopus Publications

Scopus Publications

  • Does it still make sense to talk about carbapenem-sparing?
    Rita Murri, Pierluigi Del Vecchio, Francesca Giovannenze, Federico Frondizi, Gabriele Maria Leanza, Eleonora Taddei, Giulia De Angelis, Maurizio Sanguinetti, Carlo Torti
    Clinical Microbiology and Infection, 2026
  • Impact of a post-prescription audit and feedback antimicrobial stewardship intervention on inappropriate carbapenem prescribing: An interrupted time series analysis
    Flavio Sangiorgi, Pierluigi Del Vecchio, Eugenia Magrini, Emanuele Rando, Beatrice Liguoro, Alessia Frater, Francesca Giovannenze, Massimo Fantoni, Carlo Torti, Rita Murri
    Jac Antimicrobial Resistance, 2025
    Background Antimicrobial stewardship programs (ASPs) are essential to improve antibiotic prescribing. This study evaluated the impact of a post-prescription audit and feedback intervention on carbapenem prescribing appropriateness in a large university hospital. Methods This retrospective observational study utilized interrupted time series (ITS) analysis, employing an Autoregressive Integrated Moving Average (ARIMA) model, to assess carbapenem prescribing across three consecutive phases: a 12-month pre-intervention, a 6-month intervention, and a 6-month post-intervention follow-up. Carbapenem prescribing appropriateness was retrospectively evaluated using an in-house developed algorithm, based on international and national guidelines and institutional protocols. The intervention involved bedside consultations by infectious diseases specialists employing a post-prescription audit with face-to-face feedback. Results We evaluated 1825 carbapenem therapies, primarily prescribed for suspected/confirmed bloodstream infections (46%, 843/1825). Among these, 458 (25%) were deemed inappropriate, mainly due to unnecessarily broad-spectrum use (72%, 331/458). The ITS-ARIMA model showed an immediate 11% reduction in the rate of inappropriate prescriptions during the first month of intervention phase (P = 0.001), followed by a non-significant downward trend during the remaining intervention period. However, an immediate 14.9% increase in inappropriate prescriptions was observed at the onset of the post-intervention phase (P = 0.001), indicating a rebound effect after the withdrawal of the active stewardship intervention. Conclusions Implementing a post-prescription audit and face-to-face feedback intervention was associated with a short-term improvement in carbapenem prescribing appropriateness. We observed a reduction in the trend of inappropriateness, although this change was not statistically significant. Future studies should investigate strategies for implementing sustainable ASPs optimizing human resources and time investment.
  • Risk factors for 30-Day mortality and the role of empirical therapy in Pseudomonas aeruginosa bloodstream infections
    Nicholas Geremia, Federico Giovagnorio, Antonio Vena, Silvia Corcione, Maddalena Giannella, Simone Mornese Pinna, Francesca Giovannenze, Renato Pascale, Davide Fiore Bavaro, Beatrice Brusasco, Vincenzo Scaglione, Malgorzata Mikulska, Veronica Vassia, Marco Merli, Daniele Roberto Giacobbe, Andrea Marino, Giuseppe Accurso, Gabriele Pagani, Domenico Faliero, Benedetta Fumarola, Michele Bartoletti, Pierluigi Viale, Francesco Giuseppe De Rosa, Matteo Bassetti, and
    Infection, 2025
  • The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp.
    Federico Frondizi, Gabriele Maria Leanza, Marta Chiuchiarelli, Francesca Catania, Flavio Sangiorgi, Francesca Giovannenze, Eleonora Taddei, Enrica Tamburrini, Carlo Torti, Giancarlo Scoppettuolo
    Open Forum Infectious Diseases, 2025
    Oritavancin is emerging as a potential alternative to standard antibiotic regimens in the treatment of infective endocarditis caused by gram-positive bacteria, though evidence remains limited. We hereby report 7 cases of enterococcal endocarditis treated with oritavancin as consolidation therapy, resulting in 6 cures and 1 relapse.
  • Treatment of Stenotrophomonas malthophilia bloodstream infections from guidance to real life: multicenter retrospective cohort study
    Renato Pascale, Angelo Maccaro, Mena Gallo, Francesca Giovannenze, Monica Tontodonati, Stefania Chiappetta, Gabriele Pagani, Michele Bartoletti, Francesco Giuseppe De Rosa, Matteo Bassetti, Silvia Corcione, Antonio Vena, Maddalena Giannella
    Journal of Infection and Chemotherapy, 2025
  • Effect of an educational antimicrobial stewardship programme on antibiotic prescriptions' appropriateness in three medical units of a large university hospital: an interrupted time series analysis
    F. Giovannenze, P. Del Vecchio, F. Frondizi, E. Rando, G.M. Leanza, M.M. Gross, A. Frater, E. Magrini, B. Liguoro, F. Sangiorgi, M. Fantoni, C. Torti, R. Murri
    Journal of Hospital Infection, 2025
    BACKGROUND: Antimicrobial stewardship (AMS) programmes aim to enhance antibiotic prescription quality, reduce antibiotic use, and combat multi-drug-resistant pathogens. However, the optimal AMS intervention for different clinical settings remains unclear, with previous studies predominantly focusing on antibiotic consumption rather than prescription appropriateness. AIM: This study aimed to evaluate the impact of an education-based AMS intervention on antibiotic prescription appropriateness in three medical units of a 1500-bed university hospital. METHODS: We conducted a retrospective interventional, interrupted time series study, to test the effect of an educational programme in three medical units of our 1500-bed university hospital in Rome, from June 2018 to October 2019. The intervention comprised six educational meetings held over 3 months (December 2018 to February 2019). The primary outcome was the appropriateness of antibiotic prescriptions, with in-hospital survival as a secondary outcome. FINDINGS: Of 609 antibiotic prescriptions evaluated, the programme led to a significant and sustained reduction in inappropriate prescriptions in one unit (change in level: -18.15%, P<0.01; change in trend: -3.21%, P=0.01), while it failed to demonstrate a significant reduction in the other two units and globally in the three units. CONCLUSION: The same educational AMS programme led to variable results in terms of antibiotic appropriateness in three medical units with similar structural and organizational features. Larger and more tailored high-quality AMS interventional studies are needed to better understand the impact of educational programmes on the appropriateness of antibiotic prescriptions.
  • Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?
    Davide Fiore Bavaro, Giuseppe Accurso, Silvia Corcione, Antonio Vena, Michela Schenone, Lucia Diella, Teresa Fasciana, Maddalena Giannella, Daniele Roberto Giacobbe, Simone Mornese Pinna, Renato Pascale, Francesca Giovannenze, Nicholas Geremia, Andrea Marino, Pierluigi Viale, Francesco Giuseppe De Rosa, Matteo Bassetti, Michele Bartoletti
    Journal of Antimicrobial Chemotherapy, 2025
    Background Pseudomonas aeruginosa bloodstream infections (Pa-BSIs) are still a major cause of mortality in ICUs, posing many treatment uncertainties. Methods This multicentre, retrospective study analysed data from 14 Italian hospitals, including all consecutive adults developing Pa-BSI in ICU during 2021–22 and treated with antibiotics for at least 48 h. The primary aim was to identify predictors of 30 day mortality using Cox regression. Results were adjusted with inverse probability of treatment weighting (IPTW) and for immortal time bias. Results Overall, 170 patients were included. High-risk BSI (source: lung, intra-abdominal, CNS) occurred in 118 (69%) patients, and 54 (32%) had septic shock. In 37 (22%), 73 (43%), 12 (7%) and 48 (28%) the definitive backbone therapy was piperacillin/tazobactam, carbapenems, colistin or new antipseudomonal cephalosporins (ceftolozane/tazobactam, n = 20; ceftazidime/avibactam, n = 22; cefiderocol, n = 6), respectively. Moreover, 58 (34%) received a second drug as combination therapy. The incidence of 30 day all-cause mortality was 27.6% (47 patients). By Cox regression, Charlson comorbidity index, neutropenia, septic shock and high-risk BSI were independent predictors of 30 day mortality, while previous colonization by P. aeruginosa, use of antipseudomonal cephalosporins as definitive treatment, and combination therapy were shown to be protective. However, after IPTW adjustment, only the protective effect of antipseudomonal cephalosporins was confirmed (adjusted HR = 0.27, 95% CI = 0.10–0.69), but not for combination therapy. Hence, the treatment effect was calculated: antipseudomonal cephalosporins significantly reduced mortality risk [−17% (95% CI = −4% to −30%)], while combination therapy was beneficial only in the case of septic shock [−66% (95% CI = −44% to −88%]. Conclusions In ICU, antipseudomonal cephalosporins may be the preferred target therapy for the treatment of Pa-BSI; in addition, initial combination therapy may be protective in the case of septic shock.
  • Pseudomonas aeruginosa bloodstream infections in internal medicine wards: A large Italian multicenter retrospective study
    Silvia Corcione, Simone Mornese Pinna, Antonio Vena, Michela Schenone, Maura Sanino, Renato Pascale, Emanuele Pivetta, Daniele Roberto Giacobbe, Maddalena Giannella, Nour Shbaklo, Francesca Giovannenze, Nicholas Geremia, Malgorzata Mikulska, Davide Bavaro, Eleonora Taddei, Vincenzo Scaglione, Veronica Vassia, Benedetta Fumarola, Michele Bartoletti, Pierluigi Viale, Matteo Bassetti, Francesco Giuseppe De Rosa, and
    Plos One, 2025
    Introduction This large, multicenter, Italian retrospective study aimed to describe clinical characteristics and risk factors associated with 30-day mortality in patients with Pseudomonas aeruginosa bloodstream infections (PA-BSI) admitted to internal medicine wards (IMW). To enhance clinical decision-making, we also developed and internally validated a bedside prognostic model to predict the 30-day mortality risk. Methods We conducted a retrospective, multicenter cohort study across 14 public hospitals in Italy, analyzing all adult patients admitted to IMW with PA-BSI between 2021 and 2022. Results Out of 285 eligible patients with PA-BSI, the median age was 73 years, and septic shock occurred in 13.3% of cases. Less than 5% of PA-BSI were caused by difficult-to-treat resistant P. aeruginosa (DTR-PA). Encouragingly, appropriate empiric therapy was administered in 69.8% of patients, yet the overall 30-day mortality remained 22.5%. Cox regression analysis identified age, and urinary catheter use as significant risk factors for mortality. Conversely, adequate source control and targeted therapy emerged as protective factors. Multivariate analysis confirmed septic shock at bloodstream infection onset (HR 6.96; 95% CI, 1.72–28.12) as a strong independent predictor of mortality, whereas effective source control (HR 0.152; 95% CI, 0.039–0.59) significantly improved survival odds. Using these insights, we developed a practical prognostic model capable of estimating the 30-day mortality risk, providing clinicians with a valuable predictive tool at the bedside. Conclusions PA-BSI in IMWs is characterized by a relatively low incidence of septic shock and rate of resistance, alongside high rates of appropriate empiric therapy. Despite these favorable factors, meropenem may represent a valuable therapeutic option for PA-BSI with severe presentations in this setting since mortality remains substantial (22.5%). Our findings underscore the critical importance of early source control and identify septic shock as a key predictor of mortality even in the setting of IMW. The proposed bedside nomogram model could empower clinicians to identify high-risk patients early, facilitating timely interventions and improving outcomes in this vulnerable population.
  • Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review
    Antonio Vena, Laura Mezzogori, Nadia Castaldo, Silvia Corcione, Renato Pascale, Maddalena Giannella, Simone Mornese Pinna, Daniele Roberto Giacobbe, Davide Fiore Bavaro, Vincenzo Scaglione, Benedetta Fumarola, Gabriele Pagani, Francesco Giuseppe De Rosa, Michele Bartoletti, Matteo Bassetti, , Giuseppe Accurso, Davide Fiore Bavaro, Stefania Chiappetta, Domenico Faliero, Benedetta Fumarola, Nicholas Geremia, Francesca Giovannenze, Angelo Maccaro, Andrea Marino, Marco Merli, Gabriele Pagani, Alessia Sardanelli, Vincenzo Scaglione, Monica Tontodonati, Veronica Vassia
    Infectious Diseases and Therapy, 2025
    INTRODUCTION: The treatment of Stenotrophomonas maltophilia bloodstream infections (BSI) remains challenging due to the organism's intrinsic multidrug resistance and the potential side effects of commonly used first-line antibiotics. METHODS: Here, we describe four cases of S. maltophilia BSI treated with cefiderocol (≥ 72 h) in different Italian hospitals. Additionally, we conducted a PubMed search to identify other studies reporting cases of S. maltophilia BSI managed with cefiderocol. RESULTS: We reviewed a total of 8 cases of S. maltophilia BSI [median age 52.5 years (Q1-Q3 27.5-61.0), 50% males] treated with cefiderocol, including ours. BSI sources were mainly central venous catheters (62.5%) and the lower respiratory tract (25.0%). Cefiderocol was used as first-line therapy in 87.5% of patients (7/8), with a median treatment duration of 14 days (IQR 6.2-16.0). Combination therapy was administered in 62.5% of cases. Infection source control was required in 75.0% and achieved in 40.0%. Clinical success was observed in 62.5% of patients, with microbiological eradication in 87.5%. In-hospital mortality occurred in 37.5% of cases, with one death directly attributable to S. maltophilia. No significant differences were observed in terms of outcomes between cefiderocol monotherapy and combination therapy. CONCLUSIONS: Based on our findings and a review of the literature, cefiderocol-based regimens show promise as an effective treatment option for S. maltophilia BSI, warranting further investigation in larger studies.
  • A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis
    Gabriele Maria Leanza, Emanuele Rando, Federico Frondizi, Eleonora Taddei, Francesca Giovannenze, Juan P. Horcajada, Giancarlo Scoppettuolo, Carlo Torti
    Infection, 2025
    Introduction Dalbavancin is an antibiotic characterized by an extended half-life and efficacy against methicillin-resistant Staphylococci. Currently, there are only narrative reviews summarizing the evidence about the use of dalbavancin for infective endocarditis (IE), many of which are focused primarily on its use as consolidation therapy. For this reason, we conducted a systematic review to describe the clinical efficacy and the safety of dalbavancin in IE treatment. Methods We searched for available evidence using the MEDLINE (PubMed), Embase, Scopus, Cochrane Library and Web of Science libraries, with no restrictions regarding the publication year. The risk of bias was performed using the Cochrane ROBINS-I tool for the comparative studies and the Newcastle-Ottawa Scale for descriptive studies. Results Nine studies were included. All of them were observational. Native valve endocarditis was the most common kind of IE found in the studies’ populations (128/263, 48.7%), followed by prosthetic valve endocarditis, and cardiovascular implantable electronic device-related endocarditis. Coagulase-negative Staphylococci were the most common pathogens isolated (83/269, 30.1%), followed by S. aureus, Enterococci spp and Streptococci spp. Five out of nine studies documented a clinical failure rate of less than 10%. Dalbavancin showed a favourable safety profile. Dalbavancin appears to be a promising option for the consolidation therapy of IE. However, further studies comparing dalbavancin with standard of care are needed. PROSPERO registration number CRD42023430032.
  • Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study
    Antonio Vena, Michela Schenone, Silvia Corcione, Maddalena Giannella, Renato Pascale, Daniele Roberto Giacobbe, Marco Muccio, Simone Mornese Pinna, Bianca Pari, Francesca Giovannenze, Nicholas Geremia, Malgorzata Mikulska, Eleonora Taddei, Flavio Sangiorgi, Davide Fiore Bavaro, Vincenzo Scaglione, Veronica Vassia, Marco Merli, Michele Bartoletti, Pierluigi Viale, Francesco Giuseppe De Rosa, Matteo Bassetti
    Journal of Antimicrobial Chemotherapy, 2024
  • Studying Cardiac infection by tracking clinical data flow: Experiences using a REDCap instance
    Giuseppe Pezzi, Maria Ghita Cassano, Francesca Giovannenze, Eleonora Taddei, Giancarlo Scoppettuolo, Pietro Hiram Guzzi, Carlo Torti, Pierangelo Veltri
    Proceedings 2024 IEEE International Conference on Bioinformatics and Biomedicine Bibm 2024, 2024
  • The expanding role of 16s ribosomal RNA PCR in the management of patients with infective endocarditis undergoing cardiac surgery
    Natalia Pavone, Federico Cammertoni, Maria Calabrese, Piergiorgio Bruno, Giancarlo Scoppettuolo, Antonella Lombardo, Francesca Giovannenze, Eleonora Taddei, Barbara Fiori, Tiziana D’Inzeo, Gessica Cutrone, Giulia Iannaccone, Niccolò Del Zanna, Massimo Massetti
    Frontiers in Cardiovascular Medicine, 2024
  • Outbreaks of autochthonous Dengue in Lazio region, Italy, August to September 2023: preliminary investigation
    Gabriella De Carli, Fabrizio Carletti, Martina Spaziante, Cesare Ernesto Maria Gruber, Martina Rueca, Pietro Giorgio Spezia, Valentina Vantaggio, Alessandra Barca, Claudio De Liberato, Federico Romiti, Maria Teresa Scicluna, Stefania Vaglio, Mariano Feccia, Enrico Di Rosa, Francesco Paolo Gianzi, Cristina Giambi, Paola Scognamiglio, Emanuele Nicastri, Enrico Girardi, Fabrizio Maggi, Francesco Vairo, and
    Eurosurveillance, 2023
  • Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study
    Emanuele Rando, Salvatore Lucio Cutuli, Flavio Sangiorgi, Eloisa Sofia Tanzarella, Francesca Giovannenze, Giulia De Angelis, Rita Murri, Massimo Antonelli, Massimo Fantoni, Gennaro De Pascale
    Jac Antimicrobial Resistance, 2023
  • Cutaneous diphtheria most likely due to exposure in a detention camp in Libya
    Francesco Taccari, Federico Frondizi, Federica Salvati, Francesca Giovannenze, Paola Del Giacomo, Fernando Damiano, Teresa Spanu, Rosalia Graffeo, Giulia Menchinelli, Melinda Mariotti, Maurizio Sanguinetti, Federica Castri, Andreas Neumayr, Enrico Brunetti, Giulia Errico, Rita Murri, Roberto Cauda, Giancarlo Scoppettuolo
    Journal of Travel Medicine, 2023
  • Empiric Antifungal Therapy for Intra-Abdominal Post-Surgical Abscesses in Non-ICU Patients
    Eleonora Taddei, Francesca Giovannenze, Emanuela Birocchi, Rita Murri, Lucia Cerolini, Francesco Vladimiro Segala, Pierluigi Del Vecchio, Francesco Taccari, Massimo Fantoni
    Antibiotics, 2023
  • Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)
    Ilaria Mastrorosa, Roberta Gagliardini, Francesco Vladimiro Segala, Annalisa Mondi, Patrizia Lorenzini, Carlotta Cerva, Eleonora Taddei, Francesca Bai, Alessandra Vergori, Marcantonio Negri, Carmela Pinnetti, Stefania Cicalini, Rita Murri, Valentina Mazzotta, Marta Camici, Silvia Mosti, Teresa Bini, Gaetano Maffongelli, Alessia Beccacece, Eugenia Milozzi, Marco Iannetta, Silvia Lamonica, Marisa Fusto, Maria Maddalena Plazzi, Sandrine Ottou, Miriam Lichtner, Massimo Fantoni, Massimo Andreoni, Loredana Sarmati, Roberto Cauda, Enrico Girardi, Emanuele Nicastri, Antonella D'Arminio Monforte, Fabrizio Palmieri, Antonella Cingolani, Francesco Vaia, Andrea Antinori, Chiara Agrati, Massimo Andreoni, Andrea Antinori, Francesca Bai, Alessia Beccacece, Filippo Barreca, Maria Paola Bertuccio, Teresa Bini, Evangelo Boumis, Marta Camici, Roberto Cauda, Carlotta Cerva, Stefania Cicalini, Antonella Cingolani, Antonella D'Arminio Monforte, Angela D'Urso, Margherita De Masi, Federico De Zottis, Cosmo Del Borgo, Francesco Di Gennaro, Arianna Emiliozzi, Massimo Fantoni, Laura Fondaco, Marisa Fusto, Roberta Gagliardini, Francesca Giovannenze, Elisabetta Grilli, Marco Iannetta, Daniele Iodice, Miriam Lichtner, Patrizia Lorenzini, Gaetano Maffongelli, Erminia Masone, Barbara Massa, Ilaria Mastrorosa, Valentina Mazzotta, Paola Mencarini, Eugenia Milozzi, Annalisa Mondi, Silvia Mosti, Rita Murri, Marcantonio Negri, Emanuele Nicastri, Gian Piero Oliva, Giovanna Onnelli, Sandrine Ottou, Pier Giorgio Pace, Fabrizio Palmieri, Jessica Paulicelli, Carmela Pinnetti, Maria Maddalena Plazzi, Loredana Sarmati, Francesco Vladimiro Segala, Chiara Sorace, Eleonora Taddei, Alessandra Vergori, Pietro Vitale
    Eclinicalmedicine, 2023
  • Prevention and antibiotic therapy of hip periprosthetic joint infections
    Francesca GIOVANNENZE, Francesco TACCARI, Massimo FANTONI
    Minerva Orthopedics, 2022
  • A review of recent advances in the treatment of adults with complicated urinary tract infection
    Emanuele Rando, Francesca Giovannenze, Rita Murri, Emilio Sacco
    Expert Review of Clinical Pharmacology, 2022
  • Post-prescription audit plus beta-d-glucan assessment decrease echinocandin use in people with suspected invasive candidiasis
    Rita Murri, Sara Lardo, Alessio De Luca, Brunella Posteraro, Riccardo Torelli, Giulia De Angelis, Francesca Giovannenze, Francesco Taccari, Lucia Pavan, Lucia Parroni, Maurizio Sanguinetti, Massimo Fantoni
    Medicina Lithuania, 2021
  • Predictors of mortality among adult, old and the oldest old patients with bloodstream infections: An age comparison
    Francesca Giovannenze, Rita Murri, Claudia Palazzolo, Francesco Taccari, Marta Camici, Teresa Spanu, Brunella Posteraro, Maurizio Sanguinetti, Roberto Cauda, Graziano Onder, Massimo Fantoni
    European Journal of Internal Medicine, 2021
  • Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention
    Francesco Vladimiro Segala, Rita Murri, Eleonora Taddei, Francesca Giovannenze, Pierluigi Del Vecchio, Emanuela Birocchi, Francesco Taccari, Roberto Cauda, Massimo Fantoni
    Antimicrobial Resistance and Infection Control, 2020
  • Day 10 post-prescription audit optimizes antibiotic therapy in patients with bloodstream infections
    Rita Murri, Claudia Palazzolo, Francesca Giovannenze, Francesco Taccari, Marta Camici, Teresa Spanu, Brunella Posteraro, Maurizio Sanguinetti, Roberto Cauda, Massimo Fantoni
    Antibiotics, 2020
  • Management and prevention of cranioplasty infections
    Paolo Frassanito, Flavia Fraschetti, Federico Bianchi, Francesca Giovannenze, Massimo Caldarelli, Giancarlo Scoppettuolo
    Child S Nervous System, 2019
  • Systemic antibiotic treatment of chronic osteomyelitis in adults
    M. Fantoni, F. Taccari, F. Giovannenze
    European Review for Medical and Pharmacological Sciences, 2019
  • Clinical and prognostic features of prosthetic joint infections caused by Enterococcus spp
    T. Ascione, G. Balato, M. Mariconda, M. Fantoni, F. Giovannenze, P. Pagliano
    European Review for Medical and Pharmacological Sciences, 2019
  • Epidemiological and clinical features of prosthetic joint infections caused by gram-negative bacteria
    M. Fantoni, S. Borrè, R. Rostagno, G. Riccio, G. Carrega, F. Giovannenze, F. Taccari
    European Review for Medical and Pharmacological Sciences, 2019
  • Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients
    Rita Murri, Marta Camici, Brunella Posteraro, Francesca Giovannenze, Francesco Taccari, Giulio Ventura, Giancarlo Scoppettuolo, Maurizio Sanguinetti, Roberto Cauda, Massimo Fantoni
    Infection and Drug Resistance, 2019
  • Incidental intraoperative diagnosis of Mycobacterium abscessus meningeal infection: a case report and review of the literature
    Francesca Giovannenze, Vito Stifano, Giancarlo Scoppettuolo, Fernando Damiano, Federico Pallavicini, Giovanni Delogu, Ivana Palucci, Alessandro Rapisarda, Cosimo Sturdà, Angelo Pompucci
    Infection, 2018
  • Systematic clinical management of patients with candidemia improves survival
    Rita Murri, Francesca Giovannenze, Marta Camici, Riccardo Torelli, Giulio Ventura, Giancarlo Scoppettuolo, Maurizio Sanguinetti, Roberto Cauda, Massimo Fantoni
    Journal of Infection, 2018
  • Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients
    Enrico Pola, F. Taccari, G. Autore, F. Giovannenze, V. Pambianco, R. Cauda, G. Maccauro, M. Fantoni
    European Spine Journal, 2018
  • Procalcitonin is useful in driving the choice of early antibiotic treatment in patients with bloodstream infections
    European Review for Medical and Pharmacological Sciences, 2018
  • A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections
    R. Murri, F. Taccari, T. Spanu, T. D’Inzeo, I. Mastrorosa, F. Giovannenze, G. Scoppettuolo, G. Ventura, C. Palazzolo, M. Camici, S. Lardo, B. Fiori, M. Sanguinetti, R. Cauda, M. Fantoni
    European Journal of Clinical Microbiology and Infectious Diseases, 2018
  • Trimethoprim–sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series
    Rita Murri, Barbara Fiori, Teresa Spanu, Ilaria Mastrorosa, Francesca Giovannenze, Francesco Taccari, Claudia Palazzolo, Giancarlo Scoppettuolo, Giulio Ventura, Maurizio Sanguinetti, Roberto Cauda, Massimo Fantoni
    Infection, 2017
  • Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis
    Rita Murri, Antonio Giulio de Belvis, Massimo Fantoni, Maria Tanzariello, Paolo Parente, Stefano Marventano, Sabina Bucci, Francesca Giovannenze, Walter Ricciardi, Roberto Cauda, Gabriele Sganga
    International Journal for Quality in Health Care, 2016
  • Initial antifungal strategy does not correlate with mortality in patients with candidemia
    R. Murri, G. Scoppettuolo, G. Ventura, M. Fabbiani, F. Giovannenze, F. Taccari, E. Milozzi, B. Posteraro, M. Sanguinetti, R. Cauda, M. Fantoni
    European Journal of Clinical Microbiology and Infectious Diseases, 2016